Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial - Eli Lilly and Company

For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%)…